Loading clinical trials...
Loading clinical trials...
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants With Recurrent or Metastatic GRPR-expressing Tumors
Conditions
Interventions
²¹²Pb-DOTAM-GRPR1
Locations
4
United States
Northwestern University Robert H Lurie Medical Research
Chicago, Illinois, United States
UK Markey Cancer Center
Lexington, Kentucky, United States
Advanced Molecular Imaging and Therapy
Glen Burnie, Maryland, United States
XCancer Omaha / Urology Cancer Center
Omaha, Nebraska, United States
Start Date
December 22, 2022
Primary Completion Date
January 1, 2027
Completion Date
May 1, 2032
Last Updated
March 20, 2026
NCT07547774
NCT06157151
NCT07040891
NCT06257264
NCT05491226
NCT07525869
Lead Sponsor
Orano Med LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions